Dyne Therapeutics, Inc. DYN
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -14.67%
- 1 year
- -29.13%
- Open
- 17.04
- Prev close
- 17.04
- Mkt cap
- 3.12B
- Vol
- 1.45M
- Avg vol
- 2.78M
- EPS
- -3.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.34
- High
- 17.19
- Forward P/E
- -5.04
- Beta
- 1.12
- Short ratio
- 7.94
- Inst. own
- 103.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 18.72
- 200-d avg
- 19.31
- 1y target
- 34.33
News
-
4 days ago benzinga.com
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15
Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.
1 week ago globenewswire.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.
-
1 month ago benzinga.com
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a…
1 month ago globenewswire.com
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a…
-
1 month ago benzinga.com
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target
Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.
1 month ago globenewswire.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
1 month ago seekingalpha.com
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.
-
1 month ago benzinga.com
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.
-
1 month ago benzinga.com
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26
Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.
1 month ago seekingalpha.com
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges…
1 month ago defenseworld.net
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors bought 20,532 call options on the stock. This is an increase of 4,325%…
1 month ago benzinga.com
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1…
1 month ago benzinga.com
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
1 month ago benzinga.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
1 month ago benzinga.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
-
1 month ago benzinga.com
Dyne Therapeutics To Demonstrate Additional One-Year Results From Phase 1/2 ACHIEVE Study Of Zeleciment Basivarsen For DM1 At Annual International Congress Of World Muscle Society
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it…
1 month ago globenewswire.com
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -
1 month ago benzinga.com
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
1 month ago defenseworld.net
Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest Position
Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 25.5% in the undefined quarter, according to its most recent 13F filing with the…
1 month ago globenewswire.com
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All…
2 months ago globenewswire.com
Dyne Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
2 months ago defenseworld.net
ADAR1 Capital Management LLC Buys Shares of 42,821 Dyne Therapeutics, Inc. $DYN
ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) in the second quarter, according to the company in its most recent 13F filing with the Securities…
2 months ago defenseworld.net
242,392 Shares in Dyne Therapeutics, Inc. $DYN Acquired by Deutsche Bank AG
Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ: DYN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
2 months ago globenewswire.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.
-
3 months ago benzinga.com
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of…
3 months ago globenewswire.com
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
3 months ago globenewswire.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
3 months ago defenseworld.net
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN
Fifth Third Bancorp purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ: DYN) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The…
3 months ago globenewswire.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
3 months ago globenewswire.com
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
-
3 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.
3 months ago benzinga.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
3 months ago benzinga.com
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.
3 months ago globenewswire.com
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
-
3 months ago benzinga.com
Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the…
-
5 months ago benzinga.com
Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basivarsen In Individuals With DM1
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage…
-
5 months ago benzinga.com
Dyne Therapeutics Submits Biologics License Application To FDA For Zeleciment Rostudirsen To Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the…
7 months ago benzinga.com
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial results and Capricor Therapeutics announced a new PDUFA date for Deramiocel BLA.
7 months ago benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
10 months ago benzinga.com
Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday
Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
10 months ago benzinga.com
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
11 months ago benzinga.com
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday